<DOC>
	<DOCNO>NCT03018691</DOCNO>
	<brief_summary>To evaluate safety , efficacy ( dose response ) pharmacokinetics 0.3 % 1 % OPA-15406 applied twice daily 4 week pediatric patient atopic dermatitis .</brief_summary>
	<brief_title>Phase 2 Study OPA-15406 Ointment Pediatric Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Diagnosis atopic dermatitis base criterion Hanifin Rajka Subjects atopic dermatitis contact dermatitis flareup define sudden intensification atopic dermatitis . Subjects active viral skin infection . Subjects current history malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>